Under Biden Administration, Will Federal Drug Pricing Transparency Efforts Continue to Outpace State Laws?
By EsqSocial Corporation 02/03/21
During 2019 and 2020, states enacted fewer laws requiring drug manufacturers to disclose pricing and related information. Initially, the slowdown may have been due to federal actions to rein in drug prices through the Trump administration’s multiple executive orders. Thereafter, states were focused on responding to the pandemic and drug pricing was understandably placed on the back burner....
By: Blank Rome LLP